Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers

SH7139, the first of a series of selective high affinity ligand (SHAL) oncology drug candidates designed to target and bind to the HLA-DR proteins overexpressed by B-cell lymphomas, has demonstrated exceptional efficacy in the treatment of Burkitt lymphoma xenografts in mice and a safety profile tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Balhorn, Rod, Balhorn, Monique Cosman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476732/
https://www.ncbi.nlm.nih.gov/pubmed/32934776
http://dx.doi.org/10.18632/oncotarget.27709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476732/
https://www.ncbi.nlm.nih.gov/pubmed/32934776
http://dx.doi.org/10.18632/oncotarget.27709

Ejemplares similares